145 related articles for article (PubMed ID: 11490509)
1. [Alpha-glucosidase inhibitor in type 2 diabetic patients. Metabolism and body weight are favorably modified].
Fehmann HC
MMW Fortschr Med; 2001 Apr; 143(17):46. PubMed ID: 11490509
[No Abstract] [Full Text] [Related]
2. Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 2002 Jan; 25(1):247-8. PubMed ID: 11772929
[No Abstract] [Full Text] [Related]
3. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
Fehmann HC
Fortschr Med Orig; 2001 Jul; 119 Suppl 2():55-61. PubMed ID: 15704357
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
Kuboyama N; Hayashi I; Yamaguchi T
Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808
[No Abstract] [Full Text] [Related]
5. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
[TBL] [Abstract][Full Text] [Related]
7. HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
Faure E; Pallardo LF; Mesa J; Puig-Domingo M; García-Mayor R; Benito P; Ravella R; Artés M; López JS;
Diabetes Care; 2002 Oct; 25(10):1896-8. PubMed ID: 12351510
[No Abstract] [Full Text] [Related]
8. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
9. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
10. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Carlson RF
Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
[No Abstract] [Full Text] [Related]
11. Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Rabasa-Lhoret R; Chiasson JL
Drugs Aging; 1998 Aug; 13(2):131-43. PubMed ID: 9739502
[TBL] [Abstract][Full Text] [Related]
12. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Fehmann HC
MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
[No Abstract] [Full Text] [Related]
13. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Holman RR; Steemson J; Turner RC
Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
15. Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Kuritzky L; Samraj G; Quillen DM
Hosp Pract (1995); 1999 Sep; 34(10):43-6. PubMed ID: 10901748
[No Abstract] [Full Text] [Related]
16. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Kellerer M; Jakob S; Linn T; Haslbeck M
MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
[No Abstract] [Full Text] [Related]
17. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
18. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Campbell LK; Baker DE; Campbell RK
Ann Pharmacother; 2000 Nov; 34(11):1291-301. PubMed ID: 11098345
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
20. Miglitol for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1999 May; 41(1053):49-50. PubMed ID: 10368700
[No Abstract] [Full Text] [Related]
[Next] [New Search]